R1 RCM Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

R1 RCM hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$0.079
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

R1 RCM Inc. (NASDAQ:RCM) Shares Could Be 40% Below Their Intrinsic Value Estimate

Jun 05

R1 RCM Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 06

R1 RCM (NASDAQ:RCM) Might Have The Makings Of A Multi-Bagger

Mar 17

Is R1 RCM Inc. (NASDAQ:RCM) Trading At A 42% Discount?

Jan 06

R1 RCM slides 7% on secondary stock offering by selling shareholder

Sep 08

R1 RCM's (NASDAQ:RCM) Promising Earnings May Rest On Soft Foundations

Aug 11

R1 RCM GAAP EPS of -$0.07 misses by $0.11, revenue of $391.9M in-line

Aug 03

R1 RCM: Long-Term Growth Story Intact Following Cloudmed Acquisition

Jul 19

News Flash: Analysts Just Made A Meaningful Upgrade To Their R1 RCM Inc. (NASDAQ:RCM) Forecasts

Jun 30

R1 RCM draws bullish views at Barclays on Cloudmed acquisition

Jun 29

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von RCM in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von RCM gestiegen sind.

Dividendenrendite im Vergleich zum Markt

R1 RCM Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von RCM im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (RCM)	n/a
Untere 25 % des Marktes (US)	1.5%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Healthcare)	1.8%
Analystenprognose in 3 Jahren (RCM)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von RCM im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von RCM im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von RCM, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da RCM keine Ausschüttungen gemeldet hat.

R1 RCM Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

R1 RCM Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

R1 RCM Inc., Annual General Meeting, May 22, 2024

R1 RCM Inc. to Report Q1, 2024 Results on May 08, 2024

Consensus EPS estimates upgraded to US$0.0021 loss

Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative Sentiment

New minor risk - Earnings quality

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024

New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion.

Full year 2023 earnings: EPS misses analyst expectations

Coliseum Capital Issues an Open Letter to the Board of R1 RCM

R1 RCM Inc. Appoints Pamela L. Spikner as Principal Accounting Officer

R1 RCM Inc. (NasdaqGS:RCM) completed the acquisition of Acclara Solutions, LLC from Providence St. Joseph Health for $680 million.

R1 RCM Inc. to Report Q4, 2023 Results on Feb 27, 2024

R1 RCM Inc. Appoints Clay Ashdown as Director

R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.

R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.

R1 RCM Receives Notice Of Filing Delinquency from Nasdaq

R1 RCM Receives Notice Of Filing Delinquency from Nasdaq

R1 RCM Inc. announced delayed 10-Q filing

Price target decreased by 8.8% to US$19.53

R1 RCM Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.071 loss in 3Q 2022)

Now 26% undervalued after recent price drop

R1 RCM Inc. Announces Janie Wade Resigns from its Board of Directors

Now 20% undervalued after recent price drop

R1 RCM Inc. to Report Q3, 2023 Results on Nov 02, 2023

Calculating The Fair Value Of R1 RCM Inc. (NASDAQ:RCM)

Returns At R1 RCM (NASDAQ:RCM) Are On The Way Up

Lead Independent Director notifies of intention to sell stock

Price target increased by 7.8% to US$21.70

R1 RCM Inc. Provides Earnings Guidance for the Year of 2023

Second quarter 2023 earnings released: EPS: US$0.001 (vs US$0.069 loss in 2Q 2022)

Is Now An Opportune Moment To Examine R1 RCM Inc. (NASDAQ:RCM)?

R1 RCM Inc. to Report Q2, 2023 Results on Aug 02, 2023

Why We're Not Concerned About R1 RCM Inc.'s (NASDAQ:RCM) Share Price

Senior VP recently sold US$487k worth of stock

R1 RCM Inc. (NASDAQ:RCM) Shares Could Be 40% Below Their Intrinsic Value Estimate

President recently sold US$327k worth of stock

President notifies of intention to sell stock

R1 RCM Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

R1 RCM Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

R1 RCM (NASDAQ:RCM) Might Have The Makings Of A Multi-Bagger

CEO & Director recently bought US$1.0m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2023

Price target increased by 7.3% to US$16.18

R1 RCM Inc. to Report Q4, 2022 Results on Feb 16, 2023

Consensus forecasts updated

R1 RCM Inc. Announces Chief Financial Officer Changes

Is R1 RCM Inc. (NASDAQ:RCM) Trading At A 42% Discount?

R1 RCM Inc. Appoints Janie Wade as a Director of the Company, Effective January 1, 2023

R1 RCM Inc. Announces Retirement of Albert Zimmerli from the Board of Directors, Effective January 1, 2023

Price target decreased to US$15.55

Price target decreased to US$27.82

R1 RCM Inc. Provides Earnings Guidance for the Year 2022

R1 RCM Inc. to Report Q3, 2022 Results on Nov 08, 2022

R1 RCM slides 7% on secondary stock offering by selling shareholder

Key Executive recently sold US$1.0m worth of stock

R1 RCM Inc. Appoints Brian Dean as Director

R1 RCM's (NASDAQ:RCM) Promising Earnings May Rest On Soft Foundations

Key Executive exercised options and sold US$1.2m worth of stock

Independent Director recently sold US$270k worth of stock

Second quarter 2022 earnings: EPS misses analyst expectations

R1 RCM Inc. Provides Revenue Guidance for the Full Year of 2022

R1 RCM GAAP EPS of -$0.07 misses by $0.11, revenue of $391.9M in-line

Consensus forecasts updated

R1 RCM Inc. to Report Q2, 2022 Results on Aug 03, 2022

R1 RCM: Long-Term Growth Story Intact Following Cloudmed Acquisition

Consensus forecasts updated

New Mountain Capital Engages in Discussions with R1 RCM Inc

News Flash: Analysts Just Made A Meaningful Upgrade To Their R1 RCM Inc. (NASDAQ:RCM) Forecasts

R1 RCM Inc. Revises Revenue Guidance for the Year 2022

R1 RCM draws bullish views at Barclays on Cloudmed acquisition